WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development.
Profile & Fundamentals
WuXi Biologics: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.
Profile & Fundamentals
WuXi Biologics Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, Australia, and Brazil. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Tumor Associated Antigens ("TAA") mAb Technology, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh. It engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, production and sales of medicals, and biologics clinical and manufacturing services; research and development in relation to biologics; international sales contracting service; vaccine contract development and manufacturing organization (CDMO) and related business; development, production, and distribution of biotechnological products; and engages in investment and material supplier activities. WuXi Biologics (Cayman) Inc. was incorporated in 2014 and is headquartered in Wuxi, China.
Company profile record
WuXi Biologics
Common Stock · Health Care · Life Sciences Tools & Services
Company
- Company / asset
- WuXi Biologics
- Security type
- Common Stock
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- HQ
- 🇨🇳 China
- Head office
- No. 108, Meiliang Road, Wuxi, China
Leadership & scale
- Chief executive
- Dr. Zhisheng Chen Ph.D.
- CEO year born
- 1973
- Full-time employees
- 14.7K
- Fiscal year end
- December
Fundamentals snapshot
- Market Cap
- HKD 242.1B
- P/E
- 23.6x
- Revenue (Q2 26)
- CNY 11.8B
- Profit (Q2 26)
- CNY 2.4B
- Dividend Yield
- --
- Revenue (FY 25)
- CNY 21.8B
- Shares in public float
- 3.7B
- Insider ownership
- 10.12%
Reporting & identifiers
- Symbol
- 2269.HKEX
- Listing
- 🇭🇰 Hong Kong | Dividend Tax: 0%
- Ticker Currency
- HKD
- Income Statement Currency
- CNY
- Balance Sheet Currency
- CNY
- Cash Flow Currency
- CNY
- EPS Currency
- CNY
- Contract Type
- SPOT
- ISIN
- KYG970081173
- Asset ID
- equity_0c400d23-32bd-5ba3-bd4f-919ef066f41d
Ownership
Shares Outstanding
Latest: 4.2B | Max: 4.4B | Min: 3.9B
Latest reported ownership snapshot
As of Oct 1, 2026Float Shares
88.65%
3.7B latest reported shares
Insider Ownership
10.12%
Latest reported insider stake
Short Float
--
Latest reported short interest / float
Source tablesView ownership tables
Shares Outstanding
Annual reported shares outstanding; up to 10 reporting dates.
Scroll the table to see every column.
| Reporting date | Shares outstanding |
|---|---|
| 2017-01-01 | 3,873,463,900 |
| 2018-01-01 | 3,984,734,000 |
| 2019-01-01 | 3,883,578,000 |
| 2020-01-01 | 4,084,763,100 |
| 2021-01-01 | 4,435,762,100 |
| 2022-01-01 | 4,365,476,500 |
| 2023-01-01 | 4,347,903,100 |
| 2024-01-01 | 4,227,164,600 |
| 2025-01-01 | 4,165,792,100 |
| 2026-01-01 | 4,180,889,300 |
Top Holders
Available reported ownership records.
No reported records are available in this preview.
Earnings, Profitability & Valuation
Earnings, Profitability & Valuation
Earnings & Revenue
Earnings and Revenue Trajectory
AI Review
WuXi Biologics demonstrated genuine industrial resilience in fiscal 2025, expanding revenue by 16.7% to RMB 21.8 billion. Commercial demand accelerated further into the first half of 2026, delivering 18.4% top-line growth driven by late-stage clinical programs moving into full-scale factory production. However, the headline numbers conceal an important gap between operational progress and cash available for shareholders. In first-half 2026, management's adjusted profit surged 38.6%, but official statutory net profit rose only 4.3% to RMB 2.44 billion due to foreign-exchange losses and investment swings. The business is winning customer contracts, but accounting adjustments create a misleadingly rosy picture of net earnings.
WuXi Biologics demonstrated genuine industrial resilience in fiscal 2025, expanding revenue by 16.7% to RMB 21.8 billion. Commercial demand accelerated further into the first half of 2026, delivering 18.4% top-line growth driven by late-stage clinical programs moving into full-scale factory production. However, the headline numbers conceal an important gap between operational progress and cash available for shareholders. In first-half 2026, management's adjusted profit surged 38.6%, but official statutory net profit rose only 4.3% to RMB 2.44 billion due to foreign-exchange losses and investment swings. The business is winning customer contracts, but accounting adjustments create a misleadingly rosy picture of net earnings.
Revenue, Net Income, and Free Cash Flow
Latest: CNY 21.8B | Max: CNY 21.8B | Min: CNY -4.1B
Valuation
P/E Ratio (TTM)iPublished valuation snapshots use the earnings basis recorded with each observation. Source tables retain that basis.
Latest: 15x
Profitability & Margins
Margins and Operating Efficiency
AI Review
Profitability recovered strongly after earlier industry slowdowns, with gross profit margins reaching 46.0% in 2025. Running bioreactors near full capacity and focusing on intricate, high-value treatments like antibody-drug conjugates allowed the business to spread fixed factory costs across more production batches. Maintaining these high profit margins will become more difficult as overseas plants ramp up. Operating sterile cleanrooms in Ireland and Singapore requires paying European and American wages, which are roughly triple mainland Chinese levels. As international facilities handle a larger share of production, higher operating costs will limit future margin expansion.
Profitability recovered strongly after earlier industry slowdowns, with gross profit margins reaching 46.0% in 2025. Running bioreactors near full capacity and focusing on intricate, high-value treatments like antibody-drug conjugates allowed the business to spread fixed factory costs across more production batches. Maintaining these high profit margins will become more difficult as overseas plants ramp up. Operating sterile cleanrooms in Ireland and Singapore requires paying European and American wages, which are roughly triple mainland Chinese levels. As international facilities handle a larger share of production, higher operating costs will limit future margin expansion.
Profitability Margins
Latest: 46.0% | Max: 46.9% | Min: 14.3%
Latest Profitability Ratios as of 2025-12-31
Gross Margin
46.0%
Gross profit / revenue
Operating Margin
30.5%
Operating income / revenue
Net Margin
22.5%
Net income / revenue
FCF Margin
12.8%
Free cash flow / revenue
Source tablesView earnings, profitability & valuation tables
Revenue, Net Income, and Free Cash Flow
Annual reported results, using the source statement's recorded USD conversion. Up to 10 reporting periods; missing values are not estimated.
Scroll the table to see every column.
| Period end | Revenue (USD) | Net income (USD) | Free cash flow (USD) |
|---|---|---|---|
| 2016-12-31 | 142,306,330.94 | 20,301,582.73 | -49,922,589.93 |
| 2017-12-31 | 248,668,049.16 | 38,806,144.39 | -50,299,385.56 |
| 2018-12-31 | 368,379,796.51 | 91,655,813.95 | -155,359,883.72 |
| 2019-12-31 | 572,368,821.84 | 145,661,637.93 | -291,174,712.64 |
| 2020-12-31 | 859,476,875.96 | 258,634,915.77 | -634,533,537.52 |
| 2021-12-31 | 1,617,932,389.94 | 532,779,559.75 | -486,140,880.5 |
| 2022-12-31 | 2,212,849,275.36 | 640,621,159.42 | -47,350,289.86 |
| 2023-12-31 | 2,399,190,845.07 | 478,835,070.42 | 61,577,183.1 |
| 2024-12-31 | 2,558,270,000 | 459,737,123.29 | 176,388,493.15 |
| 2025-12-31 | 3,117,313,018.6 | 702,194,992.85 | 400,391,416.31 |
Published P/E Ratio
Published valuation snapshots retain each observation's earnings basis.
Scroll the table to see every column.
| Period end | P/E (times earnings) | Earnings basis |
|---|---|---|
| 2025-12-31 | 14.58 | Trailing four quarters |
| 2024-12-31 | 10.26 | Trailing four quarters |
| 2022-12-31 | 52.22 | Annual net income |
| 2021-12-31 | 98.79 | Annual net income |
Profitability Margins
Matching annual reporting dates. Values are percentages.
Scroll the table to see every column.
| Period end | Gross margin (%) | Operating margin (%) | Net margin (%) | Free cash flow margin (%) |
|---|---|---|---|---|
| 2016-12-31 | 39.34 | 20.38 | 14.27 | -35.08 |
| 2017-12-31 | 40.8 | 21.54 | 15.61 | -20.23 |
| 2018-12-31 | 40.16 | 34.58 | 24.88 | -42.17 |
| 2019-12-31 | 41.64 | 27.86 | 25.45 | -50.87 |
| 2020-12-31 | 45.13 | 26.76 | 30.09 | -73.83 |
| 2021-12-31 | 46.93 | 39.19 | 32.93 | -30.05 |
| 2022-12-31 | 44.04 | 28.44 | 28.95 | -2.14 |
| 2023-12-31 | 40.08 | 26.12 | 19.96 | 2.57 |
| 2024-12-31 | 40.97 | 26.63 | 17.97 | 6.89 |
| 2025-12-31 | 45.98 | 30.47 | 22.53 | 12.84 |
Public data excerpt created by iPulse AI and published by Future Edge Group FZE. Source: eodhd. Snapshot retrieved 2026-09-29.
Use is subject to the iPulse AI Terms of Service and applicable source rights. Missing inputs are not estimated. Full access includes the remaining records, research and interactive tools.
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.